BSX · XBRL financial data

Boston Scientific financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BSX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	9,913	11,888	12,682	14,240	16,747	20,074
Cost of goods and services sold	3,465	3,711	3,956	4,345	5,257	6,221
Gross profit	6,448	8,177	8,727	9,896	11,490	13,854
Selling, general and administrative	3,787	4,359	4,520	5,190	5,984	6,887
Total operating expenses	6,528	6,978	7,078	7,553	8,887	10,241
Other operating income (expense)	(362)	(218)	38	93	16	—
Operating income (loss)	(80)	1,199	1,649	2,343	2,603	3,613
Interest expense	361	341	470	265	305	349
Other income (expense)	362	218	(38)	(93)	(321)	(228)
Income tax expense (benefit)	2	36	443	393	436	493
Earnings per share, basic USD per share	(0.08)	0.69	0.45	1.08	1.26	1.96
Earnings per share, diluted USD per share	(0.08)	0.69	0.45	1.07	1.25	1.94
Weighted average shares, basic millions of shares	1,417	1,422	1,431	1,453	1,472	1,480
Weighted average shares, diluted millions of shares	1,417	1,434	1,440	1,464	1,486	1,495

Fiscal years (BSX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,734	1,925	928	865	414	1,965
Inventory	1,351	1,610	1,867	2,484	2,810	2,943
Prepaid and other current assets	751	799	731	621	831	660
Total current assets	6,694	6,317	5,760	6,514	6,920	8,794
Property and equipment, net	2,084	2,252	2,446	2,859	3,294	4,036
Right-of-use asset	458	435	386	439	449	465
Goodwill	9,951	11,988	12,920	14,387	17,089	18,282
Total assets	30,777	32,229	32,469	35,136	39,395	43,673
Accounts payable	513	794	862	942	960	1,144
Accrued liabilities	2,197	2,436	2,160	2,646	2,773	3,201
Total current liabilities	3,681	4,274	3,803	4,933	6,399	5,439
Lease liability, non-current	401	389	347	390	401	446
Retained earnings (accumulated deficit)	(2,378)	(1,392)	(750)	819	2,673	5,571
Total stockholders' equity	—	16,622	17,573	19,282	21,770	24,233
Total liabilities and equity	30,777	32,229	32,469	35,136	39,395	43,673
Common shares outstanding (cover page) millions of shares	1,417	1,427	1,435	1,467	1,476	1,484

Fiscal years (BSX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Stock-based compensation	170	194	220	233	266	299
Depreciation and amortization	1,123	1,093	1,136	1,196	1,269	1,368
Net cash from operating activities	1,508	1,870	1,526	2,503	3,435	4,534
Purchases of property and equipment	376	554	588	711	790	876
Net cash from investing activities	(411)	(1,597)	(2,011)	(2,574)	(5,687)	(2,640)
Proceeds from issuing common stock	975	0	0	—	—	—
Share repurchases	535	0	0	—	—	—
Dividends paid	28	55	55	28	0	—
Net cash from financing activities	293	(95)	(548)	5	1,814	(395)
Net change in cash	1,388	173	(1,042)	(70)	(450)	1,541

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Boston Scientific	609	5,138	1,048*	1.4B	Q3 FY26 10-QSep 30, 2026
Stryker	3,271	6,520	1,461*	380.7M	Q3 FY26 10-QSep 30, 2026
Intuitive Surgical	2,978	3,049	1,224*	346.6M	Q3 FY26 10-QSep 30, 2026
Medtronic	1,691	9,756	1,793	1.3B	Q1 FY27 10-QJul 31, 2026
3M	4,835	6,584	486*	516.7M	Q3 FY26 10-QSep 30, 2026
Becton Dickinson	708	4,983	not reported	272.4M	Q3 FY26 10-QJun 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	Q2 FY26 10-QJun 30, 2026
Resmed	1,011	1,415	422	140.7M	Q1 FY27 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.